Do analysts prefer TCRT or CALC?

CalciMedica has a consensus price target of $10.00, indicating a potential upside of 1,156.28%. Given CalciMedica's stronger consensus rating and higher possible upside, analysts plainly believe CalciMedica is more favorable than Alaunos Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CalciMedica 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, TCRT or CALC?

Alaunos Therapeutics is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alaunos Therapeutics N/A N/A -$4.18M -$2.13 N/A CalciMedica N/A N/A -$29.56M -$1.31 N/A

Is TCRT or CALC more profitable?

Alaunos Therapeutics' return on equity of -165.94% beat CalciMedica's return on equity. Company Net Margins Return on Equity Return on Assets Alaunos Therapeutics N/A -165.94% -123.50% CalciMedica N/A -863.40% -144.33%

Is MGX or CALC more profitable?

CalciMedica has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -51.23% beat CalciMedica's return on equity. Company Net Margins Return on Equity Return on Assets Metagenomi -384.61% -51.23% -36.62% CalciMedica N/A -863.40% -144.33%

Is MCRB or CALC more profitable?

Seres Therapeutics' return on equity of -130.29% beat CalciMedica's return on equity. Company Net Margins Return on Equity Return on Assets Seres Therapeutics N/A -130.29% -35.35% CalciMedica N/A -863.40% -144.33%

Do analysts rate INMB or CALC?

CalciMedica has a consensus target price of $10.00, suggesting a potential upside of 1,156.28%. Given CalciMedica's higher possible upside, analysts clearly believe CalciMedica is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 CalciMedica 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is INMB or CALC more profitable?

INmune Bio's return on equity of -103.03% beat CalciMedica's return on equity. Company Net Margins Return on Equity Return on Assets INmune Bio N/A -103.03% -77.66% CalciMedica N/A -863.40% -144.33%

Does the media prefer INMB or CALC?

In the previous week, INmune Bio had 2 more articles in the media than CalciMedica. MarketBeat recorded 4 mentions for INmune Bio and 2 mentions for CalciMedica. INmune Bio's average media sentiment score of 0.20 beat CalciMedica's score of 0.00 indicating that INmune Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment INmune Bio 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CalciMedica 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CALC or BHST?

In the previous week, CalciMedica had 1 more articles in the media than BioHarvest Sciences. MarketBeat recorded 2 mentions for CalciMedica and 1 mentions for BioHarvest Sciences. CalciMedica's average media sentiment score of 0.00 equaled BioHarvest Sciences'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CalciMedica 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioHarvest Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

CalciMedica (CALC) Competitors

$0.80 +0.04 (+5.75%)

As of 02:07 PM Eastern

Compare

CALC vs. TCRT, MGX, MCRB, INMB, and BHST

Should you buy CalciMedica stock or one of its competitors? MarketBeat compares CalciMedica with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CalciMedica include Alaunos Therapeutics (TCRT), Metagenomi (MGX), Seres Therapeutics (MCRB), INmune Bio (INMB), and BioHarvest Sciences (BHST).

How does CalciMedica compare to Alaunos Therapeutics?

Alaunos Therapeutics (NASDAQ:TCRT) and CalciMedica (NASDAQ:CALC) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

Alaunos Therapeutics has a beta of -1, suggesting that its stock price is 200% less volatile than the broader market. Comparatively, CalciMedica has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market.

Alaunos Therapeutics' return on equity of -165.94% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alaunos Therapeutics	N/A	-165.94%	-123.50%
CalciMedica	N/A	-863.40%	-144.33%

27.7% of Alaunos Therapeutics shares are owned by institutional investors. 16.1% of Alaunos Therapeutics shares are owned by company insiders. Comparatively, 28.3% of CalciMedica shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Alaunos Therapeutics is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$2.13	N/A
CalciMedica	N/A	N/A	-$29.56M	-$1.31	N/A

CalciMedica has a consensus price target of $10.00, indicating a potential upside of 1,156.28%. Given CalciMedica's stronger consensus rating and higher possible upside, analysts plainly believe CalciMedica is more favorable than Alaunos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CalciMedica	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, CalciMedica had 2 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 2 mentions for CalciMedica and 0 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 0.00 equaled CalciMedica'saverage media sentiment score.

Company	Overall Sentiment
Alaunos Therapeutics	Neutral
CalciMedica	Neutral

Summary

CalciMedica beats Alaunos Therapeutics on 8 of the 12 factors compared between the two stocks.

How does CalciMedica compare to Metagenomi?

Metagenomi (NASDAQ:MGX) and CalciMedica (NASDAQ:CALC) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

CalciMedica has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -51.23% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-51.23%	-36.62%
CalciMedica	N/A	-863.40%	-144.33%

CalciMedica has lower revenue, but higher earnings than Metagenomi. CalciMedica is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$25.21M	1.82	-$87.87M	-$2.30	N/A
CalciMedica	N/A	N/A	-$29.56M	-$1.31	N/A

Metagenomi has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market. Comparatively, CalciMedica has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

Metagenomi currently has a consensus target price of $7.00, suggesting a potential upside of 475.66%. CalciMedica has a consensus target price of $10.00, suggesting a potential upside of 1,156.28%. Given CalciMedica's higher probable upside, analysts clearly believe CalciMedica is more favorable than Metagenomi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
CalciMedica	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, CalciMedica had 2 more articles in the media than Metagenomi. MarketBeat recorded 2 mentions for CalciMedica and 0 mentions for Metagenomi. Metagenomi's average media sentiment score of 0.00 equaled CalciMedica'saverage media sentiment score.

Company	Overall Sentiment
Metagenomi	Neutral
CalciMedica	Neutral

Summary

Metagenomi beats CalciMedica on 7 of the 13 factors compared between the two stocks.

How does CalciMedica compare to Seres Therapeutics?

Seres Therapeutics (NASDAQ:MCRB) and CalciMedica (NASDAQ:CALC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

Seres Therapeutics has higher revenue and earnings than CalciMedica. Seres Therapeutics is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	64.51	$5.70M	-$5.17	N/A
CalciMedica	N/A	N/A	-$29.56M	-$1.31	N/A

In the previous week, CalciMedica had 2 more articles in the media than Seres Therapeutics. MarketBeat recorded 2 mentions for CalciMedica and 0 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.00 equaled CalciMedica'saverage media sentiment score.

Company	Overall Sentiment
Seres Therapeutics	Neutral
CalciMedica	Neutral

Seres Therapeutics has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market. Comparatively, CalciMedica has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

Seres Therapeutics' return on equity of -130.29% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	N/A	-130.29%	-35.35%
CalciMedica	N/A	-863.40%	-144.33%

59.3% of Seres Therapeutics shares are held by institutional investors. 5.2% of Seres Therapeutics shares are held by insiders. Comparatively, 28.3% of CalciMedica shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Seres Therapeutics currently has a consensus target price of $17.00, indicating a potential upside of 222.89%. CalciMedica has a consensus target price of $10.00, indicating a potential upside of 1,156.28%. Given CalciMedica's higher possible upside, analysts plainly believe CalciMedica is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
CalciMedica	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Seres Therapeutics beats CalciMedica on 7 of the 13 factors compared between the two stocks.

How does CalciMedica compare to INmune Bio?

INmune Bio (NASDAQ:INMB) and CalciMedica (NASDAQ:CALC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

INmune Bio's return on equity of -103.03% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-103.03%	-77.66%
CalciMedica	N/A	-863.40%	-144.33%

12.7% of INmune Bio shares are held by institutional investors. 21.4% of INmune Bio shares are held by company insiders. Comparatively, 28.3% of CalciMedica shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

INmune Bio has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, CalciMedica has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

CalciMedica has lower revenue, but higher earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	1,012.70	-$45.93M	-$1.67	N/A
CalciMedica	N/A	N/A	-$29.56M	-$1.31	N/A

In the previous week, INmune Bio had 2 more articles in the media than CalciMedica. MarketBeat recorded 4 mentions for INmune Bio and 2 mentions for CalciMedica. INmune Bio's average media sentiment score of 0.20 beat CalciMedica's score of 0.00 indicating that INmune Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
INmune Bio	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CalciMedica	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CalciMedica has a consensus target price of $10.00, suggesting a potential upside of 1,156.28%. Given CalciMedica's higher possible upside, analysts clearly believe CalciMedica is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
CalciMedica	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

INmune Bio beats CalciMedica on 9 of the 15 factors compared between the two stocks.

How does CalciMedica compare to BioHarvest Sciences?

CalciMedica (NASDAQ:CALC) and BioHarvest Sciences (NASDAQ:BHST) are related small-cap companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

CalciMedica has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -32.54%. BioHarvest Sciences' return on equity of -76.03% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CalciMedica	N/A	-863.40%	-144.33%
BioHarvest Sciences	-32.54%	-76.03%	-25.30%

BioHarvest Sciences has higher revenue and earnings than CalciMedica. BioHarvest Sciences is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CalciMedica	N/A	N/A	-$29.56M	-$1.31	N/A
BioHarvest Sciences	$34.51M	1.26	-$11.14M	-$0.59	N/A

In the previous week, CalciMedica had 1 more articles in the media than BioHarvest Sciences. MarketBeat recorded 2 mentions for CalciMedica and 1 mentions for BioHarvest Sciences. CalciMedica's average media sentiment score of 0.00 equaled BioHarvest Sciences'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CalciMedica	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioHarvest Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CalciMedica has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, BioHarvest Sciences has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market.

CalciMedica currently has a consensus price target of $10.00, suggesting a potential upside of 1,156.28%. BioHarvest Sciences has a consensus price target of $10.00, suggesting a potential upside of 351.26%. Given CalciMedica's higher probable upside, equities research analysts plainly believe CalciMedica is more favorable than BioHarvest Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CalciMedica	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

BioHarvest Sciences beats CalciMedica on 6 of the 10 factors compared between the two stocks.

Get CalciMedica News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CALC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CALC vs. The Competition

Export

Metric	CalciMedica	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$12.55M	$11.44B	$6.80B	$13.01B
Dividend Yield	N/A	2.74%	2.60%	10.03%
P/E Ratio	-0.61	791.58	279.98	25.51
Price / Sales	N/A	947.06	649.35	116.02
Price / Cash	N/A	14.82	28.64	34.82
Price / Book	-1.73	10.44	11.15	6.35
Net Income	-$29.56M	$2.80B	$3.48B	$347.60M
7 Day Performance	10.89%	1.86%	2.51%	3.14%
1 Month Performance	-17.55%	-2.90%	-2.78%	-2.08%
1 Year Performance	-73.90%	155.40%	64.32%	21.27%

CalciMedica Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CALC CalciMedica	2.8855 of 5 stars	$0.80 +5.8%	$10.00 +1,156.3%	-74.4%	$12.55M	N/A	N/A	30	Upcoming Earnings Gap Up
TCRT Alaunos Therapeutics	0.5703 of 5 stars	$1.90 flat	N/A	-30.5%	$46.40M	N/A	N/A	40
MGX Metagenomi	3.0988 of 5 stars	$1.21 flat	$7.00 +478.5%	-46.2%	$45.56M	$25.21M	N/A	236	Upcoming Earnings
MCRB Seres Therapeutics	2.2587 of 5 stars	$4.65 -3.1%	$17.00 +265.6%	-64.0%	$45.01M	$790K	N/A	330	Upcoming Earnings
INMB INmune Bio	1.0414 of 5 stars	$1.69 -1.2%	N/A	-27.7%	$44.92M	$50K	N/A	10	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CALC) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CalciMedica (CALC) Competitors

CALC vs. TCRT, MGX, MCRB, INMB, and BHST

How does CalciMedica compare to Alaunos Therapeutics?

Summary

How does CalciMedica compare to Metagenomi?

Summary

How does CalciMedica compare to Seres Therapeutics?

Summary

How does CalciMedica compare to INmune Bio?

Summary

How does CalciMedica compare to BioHarvest Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALC vs. The Competition

CalciMedica Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CalciMedica (CALC) Competitors

CALC vs. TCRT, MGX, MCRB, INMB, and BHST

How does CalciMedica compare to Alaunos Therapeutics?

Which has more risk and volatility, TCRT or CALC?

Is TCRT or CALC more profitable?

Do insiders & institutionals hold more shares of TCRT or CALC?

Which has preferable earnings & valuation, TCRT or CALC?

Do analysts prefer TCRT or CALC?

Does the media refer more to TCRT or CALC?

Summary

How does CalciMedica compare to Metagenomi?

Is MGX or CALC more profitable?

Which has better earnings and valuation, MGX or CALC?

Which has more risk & volatility, MGX or CALC?

Do analysts recommend MGX or CALC?

Does the media favor MGX or CALC?

Summary

How does CalciMedica compare to Seres Therapeutics?

Which has better valuation & earnings, MCRB or CALC?

Does the media refer more to MCRB or CALC?

Which has more risk & volatility, MCRB or CALC?

Is MCRB or CALC more profitable?

Do insiders & institutionals hold more shares of MCRB or CALC?

Do analysts recommend MCRB or CALC?

Summary

How does CalciMedica compare to INmune Bio?

Is INMB or CALC more profitable?

Do institutionals & insiders have more ownership in INMB or CALC?

Which has more risk & volatility, INMB or CALC?

Which has stronger valuation and earnings, INMB or CALC?

Does the media prefer INMB or CALC?

Do analysts rate INMB or CALC?

Summary

How does CalciMedica compare to BioHarvest Sciences?

Is CALC or BHST more profitable?

Which has better earnings & valuation, CALC or BHST?

Does the media refer more to CALC or BHST?

Which has more risk & volatility, CALC or BHST?

Do analysts rate CALC or BHST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALC vs. The Competition

CalciMedica Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools